Claus Vogelmeier

54.8k total citations · 10 hit papers
515 papers, 26.2k citations indexed

About

Claus Vogelmeier is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cancer Research. According to data from OpenAlex, Claus Vogelmeier has authored 515 papers receiving a total of 26.2k indexed citations (citations by other indexed papers that have themselves been cited), including 402 papers in Pulmonary and Respiratory Medicine, 210 papers in Physiology and 37 papers in Cancer Research. Recurrent topics in Claus Vogelmeier's work include Chronic Obstructive Pulmonary Disease (COPD) Research (320 papers), Asthma and respiratory diseases (175 papers) and Respiratory Support and Mechanisms (131 papers). Claus Vogelmeier is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (320 papers), Asthma and respiratory diseases (175 papers) and Respiratory Support and Mechanisms (131 papers). Claus Vogelmeier collaborates with scholars based in Germany, United States and United Kingdom. Claus Vogelmeier's co-authors include Àlvar Agustí, Leonardo M. Fabbri, Jørgen Vestbo, Fernando J. Martínez, Paul Jones, Roberto Rodríguez-Roisin, Antonio Anzueto, Robert A. Stockley, Don D. Sin and Suzanne S. Hurd and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Claus Vogelmeier

473 papers receiving 25.4k citations

Hit Papers

Global Strategy for the Diagnosis, Management, and P... 2003 2026 2010 2018 2012 2003 2016 2016 2011 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
    2012 9.4k citations Jørgen Vestbo, Suzanne S. Hurd et al. American Journal of Respiratory and Critical Care Medicine profile →
  2. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18
    2003 699 citations Claus Vogelmeier, Robert Bals et al. profile →
  3. Treatable traits: toward precision medicine of chronic airway diseases
    2016 653 citations Àlvar Agustí, Claus Vogelmeier et al. European Respiratory Journal profile →
  4. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
    2016 547 citations Jadwiga A. Wedzicha, Donald Banerji et al. profile →
  5. Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
    2011 484 citations Claus Vogelmeier, Thomas Glaab et al. profile →
  6. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
    2020 463 citations David Halpin, Gerard J. Criner et al. American Journal of Respiratory and Critical Care Medicine profile →
  7. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision
    2022 244 citations Bartolomé R. Celli, Leonardo M. Fabbri et al. American Journal of Respiratory and Critical Care Medicine profile →
  8. COPD and multimorbidity: recognising and addressing a syndemic occurrence
    2023 112 citations Leonardo M. Fabbri, Bartolomé R. Celli et al. The Lancet Respiratory Medicine profile →
  9. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
    2024 102 citations Surya P. Bhatt, Klaus F. Rabe et al. profile →
  10. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
    2025 18 citations Surya P. Bhatt, Klaus F. Rabe et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Claus Vogelmeier Germany 65 18.9k 9.8k 2.4k 2.1k 1.8k 515 26.2k
Klaus F. Rabe Germany 91 25.9k 1.4× 18.2k 1.8× 4.6k 2.0× 2.2k 1.1× 3.5k 2.0× 585 37.6k
Robert A. Stockley United Kingdom 59 16.0k 0.8× 6.3k 0.6× 2.1k 0.9× 2.0k 0.9× 1.7k 1.0× 328 21.9k
Edwin K. Silverman United States 85 19.2k 1.0× 9.8k 1.0× 3.8k 1.6× 1.6k 0.8× 2.0k 1.1× 484 27.3k
Stephen I. Rennard United States 93 20.5k 1.1× 12.3k 1.3× 6.9k 2.9× 2.5k 1.2× 2.7k 1.5× 594 35.7k
Alberto Papi Italy 79 14.1k 0.7× 12.5k 1.3× 1.9k 0.8× 3.4k 1.7× 4.2k 2.4× 501 22.7k
Robert A. Wise United States 94 16.2k 0.9× 10.5k 1.1× 3.3k 1.4× 5.5k 2.7× 1.6k 0.9× 884 35.8k
Guy Brusselle Belgium 79 12.5k 0.7× 12.1k 1.2× 2.6k 1.1× 1.5k 0.7× 4.3k 2.4× 445 22.8k
Leonardo M. Fabbri Italy 95 27.9k 1.5× 19.0k 1.9× 3.0k 1.3× 3.6k 1.7× 3.4k 1.9× 487 39.5k
Don D. Sin Canada 80 24.9k 1.3× 12.4k 1.3× 3.1k 1.3× 3.0k 1.5× 1.7k 0.9× 505 33.7k
Emiel F.�M. Wouters Netherlands 104 27.1k 1.4× 14.6k 1.5× 4.9k 2.1× 3.4k 1.6× 2.0k 1.2× 705 41.5k

Countries citing papers authored by Claus Vogelmeier

Since Specialization
Citations

This map shows the geographic impact of Claus Vogelmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Vogelmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Vogelmeier more than expected).

Fields of papers citing papers by Claus Vogelmeier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claus Vogelmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Vogelmeier. The network helps show where Claus Vogelmeier may publish in the future.

Co-authorship network of co-authors of Claus Vogelmeier

This figure shows the co-authorship network connecting the top 25 collaborators of Claus Vogelmeier. A scholar is included among the top collaborators of Claus Vogelmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claus Vogelmeier. Claus Vogelmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2024). Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respiratory Medicine. 236. 107846–107846.
4.
Kahnert, Kathrin, Rudolf A. Jörres, Hans‐Ulrich Kauczor, et al.. (2023). Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality. Therapeutic Advances in Respiratory Disease. 17. 2673727991–2673727991. 13 indexed citations
5.
Sin, Don D., Dany Doiron, Àlvar Agustí, et al.. (2023). Air pollution and COPD: GOLD 2023 committee report. European Respiratory Journal. 61(5). 2202469–2202469. 75 indexed citations
6.
Fabbri, Leonardo M., Bartolomé R. Celli, Àlvar Agustí, et al.. (2023). COPD and multimorbidity: recognising and addressing a syndemic occurrence. The Lancet Respiratory Medicine. 11(11). 1020–1034. 112 indexed citations breakdown →
7.
Ismaila, Afisi, Katrin Haeussler, Nancy Risebrough, et al.. (2022). Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Advances in Therapy. 39(9). 3957–3978. 23 indexed citations
8.
Halpin, David, Kieran Rothnie, Victoria Banks, et al.. (2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. International Journal of COPD. Volume 17. 2417–2429. 31 indexed citations
9.
Triphan, Simon M. F., Jürgen Biederer, Oliver Weinheimer, et al.. (2021). Quantification of pulmonary perfusion abnormalities using DCE-MRI in COPD: comparison with quantitative CT and pulmonary function. European Radiology. 32(3). 1879–1890. 20 indexed citations
10.
Miravitlles, Marc, Nicolás Roche, João Lourenço Cardoso, et al.. (2018). Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. Respiratory Research. 19(1). 11–11. 23 indexed citations
11.
Roche, Nicolás, Kenneth R. Chapman, Claus Vogelmeier, et al.. (2017). Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine. 195(9). 1189–1197. 116 indexed citations
12.
Young, David, Roland Buhl, Carl-Peter Criée, et al.. (2016). A year in the life of German patients with COPD: the DACCORD observational study. International Journal of COPD. Volume 11. 1639–1646. 23 indexed citations
13.
Houben‐Wilke, Sarah, Rudolf A. Jörres, Robert Bals, et al.. (2016). Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences–Comorbidities Network Study. American Journal of Respiratory and Critical Care Medicine. 195(2). 189–197. 69 indexed citations
14.
Vestbo, Jørgen, Suzanne S. Hurd, Àlvar Agustí, et al.. (2012). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 187(4). 347–365. 9382 indexed citations breakdown →
15.
Kardos, Péter, Marion Wencker, Thomas Glaab, & Claus Vogelmeier. (2007). Avoiding Mistakes in Calculating the Number Needed to Treat in Severe COPD. American Journal of Respiratory and Critical Care Medicine. 175(12). 1347–1348. 1 indexed citations
16.
Kardos, Péter, Marion Wencker, Thomas Glaab, & Claus Vogelmeier. (2006). Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 175(2). 144–149. 245 indexed citations
17.
Behr, Jürgen, et al.. (2000). Pulmonary Glutathione Levels in Acute Episodes of Farmer's Lung. American Journal of Respiratory and Critical Care Medicine. 161(6). 1968–1971. 25 indexed citations
18.
Hirsch, Ján, Andreas Elssner, Konrad Maier, et al.. (1999). Bronchiolitis Obliterans Syndrome after (Heart–)Lung Transplantation: Impaired Antiprotease Defense and Increased Oxidant Activity. American Journal of Respiratory and Critical Care Medicine. 160(5). 1640–1646. 43 indexed citations
19.
Schwaiblmair, Martin, Hermann Reichenspurner, Christian Müller, et al.. (1999). Cardiopulmonary Exercise Testing Before and After Lung and Heart–Lung Transplantation. American Journal of Respiratory and Critical Care Medicine. 159(4). 1277–1283. 62 indexed citations
20.
Behr, Jürgen, et al.. (1997). Antioxidative and Clinical Effects of High-dose N -Acetylcysteine in Fibrosing Alveolitis. American Journal of Respiratory and Critical Care Medicine. 156(6). 1897–1901. 226 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Klaus F. Rabe Breakdown of academic impact, for papers by Robert A. Stockley Breakdown of academic impact, for papers by Edwin K. Silverman Breakdown of academic impact, for papers by Stephen I. Rennard Breakdown of academic impact, for papers by Alberto Papi Breakdown of academic impact, for papers by Robert A. Wise Breakdown of academic impact, for papers by Guy Brusselle Breakdown of academic impact, for papers by Leonardo M. Fabbri Breakdown of academic impact, for papers by Don D. Sin Breakdown of academic impact, for papers by Emiel F.�M. Wouters
Rankless by CCL
2026